Ariad Pharmaceuticals: PharmaVitae Report

ABOUT THIS REPORT

• PharmaVitae Explorer database
• Chapter structure◦ Sales and product analysis
◦ Financial analysis

• Data sourcing◦ Analyst consensus

EXECUTIVE SUMMARY

• Company introduction◦ Recent developments
◦ Corporate relationships

• Strategic overview
• SWOT analysis◦ Strengths
◦ Weaknesses
◦ Opportunities
◦ Threats

SALES AND PRODUCT ANALYSIS

• Sales overview
• Product analysis◦ Product sales

• Ponatinib◦ Chronic myeloid leukemia
◦ Acute lymphoblastic leukemia
◦ Current treatments: marketed drugs for CML do not have activity against the T315I mutation
◦ Current treatments: first-line treatment of ALL consists of combination chemotherapy regimens
◦ Clinical trials
◦ Factors affecting ponatinib approval and use
◦ Key forecasting assumptions

• Other products◦ Ridaforolimus

FINANCIAL ANALYSIS

• Financial performance overview◦ Operating costs and profit analysis, 2005–11
◦ Operating costs and profit analysis, 2011–17

APPENDIX

• References◦ Datamonitor reports

• Exchange rates

List of Tables

• Table: Ariad Pharmaceuticals product portfolio overview ($m), 2012–17
• Table: Ariad Pharmaceuticals clinical trial program includes one pivotal Phase II trial and a planned Phase III trial
• Table: Phase II PACE trial data with ponatinib
• Table: Ponatinib US sales forecast model
• Table: Ponatinib EU sales forecast model
• Table: Ariad operating revenue/cost analysis ($m), 2005–11
• Table: Ariad operating revenue/cost analysis ($m), 2011–17
• Table: Exchange rates, 2011

List of Figures

• Figure: PharmaVitae Explorer
• Figure: Ariad prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012–17
• Figure: Ariad Pharmaceuticals key product sales ($m), 2012–17
• Figure: Ariad Pharmaceuticals operating/cost performance ($m), 2005–17